Developing Therapeutics Against Virtually Any Target with New Antibody Libraries
Monoclonal antibodies have become the preferred therapeutic modality for cancer, infectious diseases, inflammatory and autoimmune disorders, and other conditions.
Twist Bioscience is on a mission to support this work, offering a Library of Libraries containing multiple pre-constructed and validated libraries against many high-value targets with which scientists can build a comprehensive and robust antibody discovery platform.
Here we introduce the latest addition to our Library of Libraries: the Hyperimmune Library.
Join our webinar with Steven Thomas from Twist Biopharma, a division of Twist Bioscience, to:
- Learn about the Hyperimmune Library for therapeutic development against virtually any target.
- Hear how the latest libraries are opening new sequence space, allowing researchers to focus on difficult-to-drug targets like GPCRs and ion channels.
- Review recent work from Twist Biopharma using the Library of Libraries against human ACE2 and the SARS-CoV-2 spike protein to find potently neutralizing candidate antibodies against the SARS-CoV-2 strain of coronavirus in under 4 weeks.
- Compare options for accessing the Library of Libraries, including licensing or partnering to fully outsource lead discovery.